EdU (5-Ethynyl-2'-deoxyuridine)
Cat. # | Quantity | Price | Lead time | Buy this product |
---|---|---|---|---|
A0540 | 5 mg | – | in stock | |
10540 | 100 mg | $120 | in stock | |
20540 | 250 mg | $195 | in stock | |
30540 | 500 mg | $345 | in stock | |
40540 | 1 g | $590 | in stock | |
60540 | 5 g | please inquire | in stock |
EdU (5-ethynyl-2’-deoxyuridine) is a nucleoside, an analog of thymidine, carrying an ethynyl group. This nucleoside behaves as a substrate for cellular DNA replication machinery. After EdU incorporation, DNA containing ethynyl groups can be ligated by click chemistry reaction with various dye azides. Fluorescent DNA can be detected with microscopy, or cells can be sorted with FACS.
Recommended protocol
Calculator
Customers also purchased with this product
Azide-PEG4-azide
PEG4 diazide is a homobifunctional linker with two azide groups. It can be used for the synthesis of dimeric molecules with a hydrophilic core by click chemistry.sulfo-Cyanine5.5 azide
sulfo-Cyanine5.5 azide is a derivative of water-soluble far-red emitting fluorescent cyanine dye. The azide group can be conjugated by either copper-catalyzed or copper-free click chemistry with alkynes and cycloalkynes.AF 343 (Coumarin)-X-azide
AF 343 (Coumarin) is a blue emitting fluorophore that can serve as a FRET donor for fluorescein (FAM). This azide derivative can be conjugated with alkynes by сlick chemistry. An extended linker arm between the fluorophore and the azide group enhances solubility and provides spatial separation between the dye and the biomolecule.General properties
Appearance: | light beige to light brown solid |
Molecular weight: | 252.22 |
CAS number: | 61135-33-9 |
Molecular formula: | C11H12N2O5 |
Solubility: | in water, DMSO |
Quality control: | NMR 1H, HPLC-MS (95%) |
Storage conditions: | Storage: 24 months after receival at -20°C in the dark. Transportation: at room temperature for up to 3 weeks. |
MSDS: | Download |
Product specifications |
Product citations
- Minutti, C.M.; Piot, C.; Pereira da Costa, M.; Chakravarty, P.; Rogers, N.; Huerga Encabo, H.; Cardoso, A.; Loong, J.; Bessou, G.; Mionnet, C.; Langhorne, J.; Bonnet, D.; Dalod, M.; Tomasello, E.; Reis e Sousa, C. Distinct ontogenetic lineages dictate cDC2 heterogeneity. Nature Immunology, 2024, 25, 448–461. doi: 10.1038/s41590-024-01745-9
- Dopeso, H.; Rodrigues, P.; Cartón-García, F.; Macaya, I.; Bilic, J.; Anguita, E.; Jing, L.; Brotons, B.; Vivancos, N.; Beà, L.; Sánchez-Martín, M.; Landolfi, S.; Hernandez-Losa, J.; Ramon y Cajal, S.; Nieto, R.; Vicario, M.; Farre, R.; Schwartz Jr, S.; van Ijzendoorn, S.C.D.; Kobayashi, K.; Martinez-Barriocanal, Á.; Arango, D. RhoA downregulation in the murine intestinal epithelium results in chronic Wnt activation and increased tumorigenesis. iScience, 2024, 27(4), 109400. doi: 10.1016/j.isci.2024.109400
- Alruwaili, M.M.; Zonneville, J.; Naranjo, M.N.; Serio, H.; Melendy, T.; Straubinger, R.M.; Gillard, B.; Foster, B.A.; Rajan, P.; Attwood, K.; Chatley, S.; Iyer, R.; Fountzilas, C.; Bakin, A.V. A synergistic two-drug therapy specifically targets a DNA repair dysregulation that occurs in p53-deficient colorectal and pancreatic cancers. Cell Reports Medicine, 2024, 5(3), 101434. doi: 10.1016/j.xcrm.2024.101434
- Swan, J.; Szabó, Z.; Peters, J.; Kummu, O.; Kemppi, A.; Rahtu-Korpela, L.; Konzack, A.; Hakkola, J.; Pasternack, A.; Ritvos, O.; Kerkelä, R.; Magga, J. Inhibition of activin receptor 2 signalling ameliorates metabolic dysfunction–associated steatotic liver disease in western diet/L-NAME induced cardiometabolic disease. Biomedicine & Pharmacotherapy, 2024, 175, 116683. doi: 10.1016/j.biopha.2024.116683
Your item has been added.
View your
cart
or
proceed to checkout
The count of items is incorrect.